急性心肌梗死早期普伐他汀治疗对血浆CD40L、金属蛋白酶-9及C反应蛋白的影响

被引：100

作者：

李江

赵水平

彭道泉

许竹梅

胡敏

机构：

[1] 中南大学湘雅医学院附属二院心内科,中南大学湘雅医学院附属二院心内科,中南大学湘雅医学院附属二院心内科,中南大学湘雅医学院附属二院心内科,中南大学湘雅医学院附属二院检验科,,,,

来源：

中华心血管病杂志 | 2003年 / 03期

关键词：

普伐他汀; 心肌梗塞,急性; CD40L; 金属蛋白酶;

D O I：

暂无

中图分类号：

R542.22 [];

学科分类号：

1002 ; 100201 ;

摘要：

目的　观察较大剂量普伐他汀治疗急性心肌梗死患者 3d后金属蛋白酶 9(MMP 9)、可溶性白细胞分化抗原 40配体 (sCD40L)及C 反应蛋白 (CRP)的变化 ,以了解短期普伐他汀治疗对斑块稳定和免疫炎症抑制的影响。方法　 35例急性心肌梗死患者随机分为常规治疗组 (无服用任何调脂药物 ,17例 )和普伐他汀组 ( 40mg/d ,18例 )治疗 ,测定治疗前后sCD40L、MMP 9、CRP和血脂水平的变化。结果　二组治疗前后血脂各组成分的变化差异均无显著性 ,而普伐他汀治疗组治疗后sCD40L、MMP 9及CRP水平分别降低 38%、48%、33%,与治疗前比较有统计学差异 (P <0 0 5 )。在普伐他汀治疗组 ,sCD40L、MMP 9的降低与TC(r =0 0 9,P =0 5 7;r =0 15 ,P =0 38)、LDL C(r =0 0 8,P =0 87;r= 0 0 3 ,P =0 83)的下降百分数之间无相关关系。结论　在急性心肌梗死的早期予以 3d的普伐他汀治疗 ,可明显减低血浆炎症因子的水平、可能有利于动脉粥样硬化斑块的稳定。

引用

页码：8 / 11

页数：4

共 12 条

[1]

Identification 92 kDa gelatinase in human coronary atherosclerotic lesions: association of active enzyme synthesis with unstable angina. Brown DL,Hibbs MS,Kearney M,et al. Circulation . 1995

[2]

CD40L activation in circulating platelets in patients with acute coronary syndrome. Lee Y,Lee WH,Lee SC,et al. Cardiology . 1999

[3]

Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Mach F,Schonbeck U,Bonnefoy JY,et al. Circulation . 1997

[4]

Perpherial blood levels of matrix metalloproteinase-2 and 9 are evelated In patients with acute coronary sndrome. Kai H,Ikeda H,Yasukawa H,et al. Journal of the American College of Cardiology . 1998

[5]

Cerivastatin, a HMG-CoA Reductase Inhibitor, Improves Endothelial Function In Elderly Diabetics winthin 3 days. Taku T,Toshio H,Hatsuyo K,et al. Circulation . 2001

[6]

Enhanced levels of soluble and membrane-bound Cd40 ligand in patients with unstable angina-possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndrome. Aukrust P,Muller F,Ueland T,et al. Circulation . 1999

[7]

Atherosclerosis-An inflammatory disease. Ross R. The New England Journal of Medicine . 1999

[8]

Reduction of atherosclerosis in mice by inhibition of CD40 signaling. Mach F,Schonbeck U,Sukhova GK,et al. Nature . 1998

[9]

Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Lutgens E,Cleutjens KBJM,Heeneman S,et al. Proceedings of the National Academy of Sciences of the United States of America . 2000

[10]

1999 World Health Organization-International Society of Hypertension Guidelines for Management of Hypertension. Chalmers J,WHO-ISHHypertension Guidelines Committee. Journal of Hypertension . 1999

← 1 2 →